KCT0000615尚未招募未知
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patients: A multicenter, open-label, phase 4 clinical study
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 99（—）
- 性别
- All
入选标准
- •1)Patients aged 18 years or more
- •2)Patients with Philadelphia chromosome positive(Ph+) chronic myeloid leukemia in chronic phase within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis. Standard conventional cytogenetic analysis must be done on bone marrow. Fluorescent In-situ Hybridization(FISH) is not allowed to be used.)
- •3)Diagnosis of Chronic Myeloid leukemia in Chronic Phase with cytogenetic confirmation for the presence of Philadelphia chromosome(cytogenetic analysis should be done on bone marrow in standard conventional method. Fluorescent In-situ Hybridization(FISH) is not allowed to be used.)
- •The chronic phase is defined when all of the following criteria are met:
- •- Blasts <15% in peripheral blood and bone marrow
- •- Sum of blasts and promyelocytes <30% in peripheral blood and bone marrow
- •- Basophils <20% in peripheral blood
- •- Platelet count =100x109/L (=100,000/mm3)
- •- No evidence of extramedullary leukemic involvement, except hepatomegaly and splenomegaly
- •4) Patients with Eastern Cooperative Oncology Group (ECOG) of 0~2
- •5) Patients with QTc<450msec on screening ECG
- •6) Patients with proper organ functions
- •- bilirubin < 1.5 x ULN
- •- creatinine < 1.5 x ULN
- •- Liver function test; AST(SGOT) and ALT(SGPT) < 2.5 x ULN
- •- alkaline phosphatase = 2.5 x ULN(only if it is not related to tumor)
- •- Serum amylase and lipase = 1.5 x ULN
- •7) Patients without any other activated malignant tumor
- •8) Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to starting administration of the investigational product .
- •9) Patients who have voluntarily written informed consent, or whose legal guardian given a written consent to participate in this clinical study
排除标准
- •1)BCR-ABL positive chronic myeloid leukemia patients with negative Philadelphia chromosome
- •2)Patients who received bone marrow suppressive anti-cancer therapy excluding Hydroxyurea or Anagrelide
- •3)Patients who have been treated with a tyrosine kinase inhibitor or anti-leukemic agent, or Hematopoietic Stem Cell Transplantation (HSCT) for longer than 2 weeks
- •4)Patients with any cardiac dysfunctions stated below:
- •-Immeasurable QT intervals on screening ECG
- •-Complete left bundle branch block
- •-Using pacemaker
- •-Congenital or known family history of Long QT Syndrome(LQTS)
- •-History or presence of clinically significant ventricular or atrial tachyarrhythmias
- •-Clinically significant brachycardia at rest(<50 times per minute)
- •-QTcF =450msec in three consecutive baseline screening ECGs
- •-History of clinically confirmed myocardial infarction
- •-History of unstable angina pectoris(within past 12 months)
- •-Uncontrolled congestive heart failure or hypertension
- •5)Patients with cytopathologically identified CNS involvement (no need for lumbar puncture prior to the clinical study if there are no symptoms)
- •6)Patients who received radiotherapy on 25% or more of bone marrow for other malignant disease in the past
- •7)Use of therapeutic coumadin derivatives(that is, warfarin, acenocoumarol, phenprocoumon)
- •8)Severe or uncontrolled chronic medical condition(that is, uncontrolled diabetes, active infection or uncontrolled infection)
- •9)Medical history of congenital or acquired bleeding disorders not related to leukemia
- •10)Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not been recovered from side effects of such therapy
- •11)Patients with another primary malignancy that is currently clinically significant
- •12)Patients who are receiving therapy with strong CYP3A4 inhibitors(e.g.,erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) or CYP3A4 inducers(e.g.,dexamthasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St.John's Wort), and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug (See link for complete list: http://medicine.iupui.edu/flockhart/table.htm.)
- •13)Patients who are currently receiving treatment with any medication that have the potential to prolong the QT interval, and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug (See link for complete list: http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm.)
- •14)Impaired gastrointestinal functions or gastrointestinal diseases that may alter the absorption of the study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastrointestinal bypass)
- •15)History of acute pancreatitis or chronic pancreatitis in the past year
- •16)Other concurrent medical conditions such as acute or chronic liver, pancreas, or severe kidney diseases
- •17)Patients who are pregnant or breast feeding
- •18)Women of childbearing potential who have not received contraceptive operation (Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.) Women of childbearing potential must have a negative pregnancy test in order to participate in this study and must maintain an effective contraceptive measure during the study. Periodical abstinence(e.g.: calend
研究者
相似试验
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20
进行中（未招募）
1 期
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870EUCTR2012-000770-36-BECHU-ULg5
招募中
不适用
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational studyProgressive fibrosing interstitial lung diseaseJPRN-UMIN000041380Department of Respiratory Medicine, Juntendo University Hospital300
进行中（未招募）
2 期
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular responseACTRN12612000851864Australasian Leukaemia and Lymphoma Group60
尚未招募
2 期
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.on-Small-Cell Lung CancerJPRN-UMIN000012515Department of Respiratory Medicine, Kumamoto University Hospital16